43 completed, 10 terminated, 9 unknown, 8 recruiting. 78 Phase 2, 14 Phase 1, 9 Phase 3.
Follow Dyspnea: new trials by email Literature Review of Dyspnea trials Research Report on Dyspnea
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy of L-menthol on Breathlessness in Asthma L-menthol, Placebo - Asthma | Phase 2 | Recruiting | Region Skane | 20 | 2026-05-07 | 2026-08-19 |
| Efficacy of L-menthol on Breathlessness in Interstitial Lung Disease L-menthol, Placebo - Interstitial Lung Disease (ILD) | Phase 2 | Recruiting | Region Skane | 20 | 2026-04-13 | 2026-04-24 |
| Inhaled Treprostinil for Dyspnea and Exercise Intolerance in Mild COPD Placebo, Treprostinil Inhalation Solution 36 mcg, Treprostinil Inhalation Solution 78 mcg - COPD (Chronic Obstructive Pulmonary Disease) | Phase 2 | Active not recruiting | University of Alberta | 20 | 2025-06-05 | 2026-11-05 |
| A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma PF-07275315, Placebo - Asthma | Phase 2 | Recruiting | Pfizer | 252 | 2025-05-20 | 2026-11-06 |
| ExoFlo™ Infusion for Post-Acute COVID-19 and Chronic Post-COVID-19 Syndrome Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles, Saline - Covid19, Postviral Syndrome | Phase 1 / Phase 2 | Withdrawn | Direct Biologics, LLC | 2024-11-01 | 2024-11-22 | |
| The Effect of Inhaled Nitric Oxide on Dyspnea and Exercise Tolerance in Interstitial Lung Disease. Nitric Oxide, Placebo - Dyspnea | Phase 1 / Phase 2 | Withdrawn | University of Alberta | 2024-09-01 | 2024-09-19 | |
| Structured Personalized Oxygen and Supportive Therapies for Dyspnea in Oncology SPOT-ON Early Start, SPOT-ON Delayed Start - Dyspnea | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 150 | 2024-06-11 | 2026-09-24 |
| Breathe Easier With Tadalafil Therapy for Dyspnea in COPD-PH Tadalafil, Placebo - Chronic Obstructive Pulmonary Disease, Pulmonary Hypertension | Phase 2 | Recruiting | VA Office of Research and Development | 126 | 2024-04-01 | 2026-05-15 |
| The Impact of Inhaled Furosemide and Perorally Administered Levodropropizine on Dyspnea in Patients With Respiratory Diseases Furosemide 40 mg, Levodropropizine, Placebo - saline - Dyspnea | Phase 2 / Phase 3 | Unknown | University Hospital Hradec Kralove | 102 | 2024-02-27 | 2024-04-16 |
| 129Xe MRI Cardiopulmonary Hyperpolarized Xe129, Oxygen Administration - Interstitial Lung Disease, Chronic Thromboembolic Pulmonary Hypertension | Phase 2 | Recruiting | Bastiaan Driehuys | 125 | 2024-01-12 | 2026-02-04 |
| Impact of Long-acting Bronchodilator- -Corticoid Inhaled Therapy on Ventilation, Lung Function and Breathlessness TRIXEO AEROSPHERE - Copd | Phase 1 / Phase 2 | Recruiting | University Hospital, Lille | 35 | 2023-09-29 | 2025-12-18 |
| Effect of Diuretics Withdrawal in Chronic Heart Failure With Reduced Ejection Fraction Diuretics withdrawal, Diuretics maintenance - Heart Failure, Electric Impedance | Phase 2 | Completed | Maimónides Biomedical Research Institute of Córdoba | 98 | 2022-12-19 | 2024-11-04 |
| Oral Sildenafil for Exercise Capacity, Dyspnea and Cardiopulmonary Function in COPD Sildenafil Citrate, Placebo - Chronic Obstructive Pulmonary Disease | Phase 2 | Recruiting | University of Alberta | 160 | 2022-03-01 | 2026-11-05 |
| Study of Hesperidin Therapy on COVID-19 Symptoms (HESPERIDIN) Hesperidin, Placebo - Covid19, Anosmia | Phase 2 | Completed | Montreal Heart Institute | 216 | 2021-02-18 | 2022-04-08 |
| Inhaled ZYESAMI™ (Aviptadil Acetate) for the Treatment of Severe COVID-19 ZYESAMI™ (aviptadil acetate), Placebo, Nebulized administration of ZYESAMI™ or Placebo - SARS-CoV 2, COVID | Phase 2 / Phase 3 | Terminated | APR Applied Pharma Research s.a. | 144 | 2021-02-15 | 2023-02-03 |
| Low Dose Morphine to Relieve Dyspnea in Acute Respiratory Failure (OPIDYS) Chlorhydrate de morphine, NaCl 0,9%, - Acute Respiratory Failure | Phase 2 | Completed | Assistance Publique - Hôpitaux de Paris | 23 | 2020-12-16 | 2022-10-25 |
| Pemziviptadil (PB1046), a Long-acting, Sustained Release Human VIP Analogue, Intended to Provide Clinical Improvement to Hospitalized COVID-19 Patients at High Risk for Rapid Clinical Deterioration and Acute Respiratory Distress Syndrome (ARDS). Pemziviptadil (PB1046), Low Dose (10 mg) Control - Acute Respiratory Distress Syndrome, Coronavirus | Phase 2 | Terminated | PhaseBio Pharmaceuticals Inc. | 54 | 2020-07-15 | 2020-12-11 |
| MultiStem Administration for COVID-19 Induced ARDS (MACoVIA) MultiStem, Placebo - ARDS | Phase 2 / Phase 3 | Terminated | Healios K.K. | 22 | 2020-04-28 | 2026-10-16 |
| Nitric Oxide Gas Inhalation Therapy for Mild/Moderate COVID19 Infection Nitric Oxide - Coronavirus Infections, Pneumonia, Viral | Phase 2 | Withdrawn | Xijing Hospital | 2020-03-01 | 2020-03-24 | |
| Impact of Inhaled PT003 on Complexity and Variability of Tidal Breathing and Oscillatory Mechanics in Stable COPD Patient Formoterol-glycopyrronium co suspension (PT003) - Copd | Phase 2 | Terminated | University Hospital, Lille | 4 | 2020-01-14 | 2026-02-20 |
Showing 20 of 78. Sign in to see all of them.
Pulmonary Disease, Chronic Obstructive (18) · Asthma (11) · Heart Failure (6) · Respiratory Sounds (6) · COVID-19 (5) · Neoplasms (5) · Hypertension, Pulmonary (4) · Lung Diseases (4) · Lung Diseases, Interstitial (4) · Motor Activity (4) · Cough (3) · Pulmonary Arterial Hypertension (3) · Airway Obstruction (2) · Bronchitis, Chronic (2)
Pathological Conditions, Signs and Symptoms (78) · Respiration Disorders (78) · Signs and Symptoms (78) · Respiratory Tract Diseases (77) · Signs and Symptoms, Respiratory (77) · Lung Diseases (42) · Lung Diseases, Obstructive (30) · Pathologic Processes (23) · Disease Attributes (19) · Chronic Disease (18) · Bronchial Diseases (13) · Immune System Diseases (13) · Hypersensitivity (12) · Hypersensitivity, Immediate (11) · Cardiovascular Diseases (10)
Surveys and Questionnaires (5) · Dexamethasone (3) · Fentanyl (3) · Furosemide (3) · Nitric Oxide (3) · Calcium Dobesilate (2) · Epinephrine (2) · Menthol (2) · Midazolam (2) · Oxygen (2) · Saline Solution (2) · Sodium Chloride (2) · Sugars (2) · Tiotropium Bromide (2) · indacaterol (2)
M.D. Anderson Cancer Center (10) · Novartis Pharmaceuticals (7) · University of Alberta (5) · Amphastar Pharmaceuticals, Inc. (3) · Assistance Publique - Hôpitaux de Paris (2) · Beth Israel Deaconess Medical Center (2) · Region Skane (2) · University Hospital, Lille (2) · University of Illinois at Chicago (2) · University of Sao Paulo (2) · APR Applied Pharma Research s.a. (1) · Abgenix (1) · American University of Beirut Medical Center (1) · Assiut University (1) · Bastiaan Driehuys (1)
United States (39) · Canada (11) · United Kingdom (10) · Germany (9) · France (7) · Belgium (5) · Czechia (3) · Italy (3) · Netherlands (3) · Sweden (3) · Argentina (2) · Australia (2) · Brazil (2) · Bulgaria (2) · Hungary (2)
David Hui, MD (8) · David Hui (2) · Margaret K Covey, PhD, RN (2) · Alberto Torres Zamudio, MD (1) · Ashley Bjorklund, MD (1) · Bill Arana (1) · Celso Carvalho, Dr. (1) · Claudia Bausewein, PhD MD MSc (1) · Dalane W Kitzman, MD (1) · Daniel Martin, Ph.D., PT (1) · Dennis Jensen, Ph.D (1) · Dennis Jensen, Ph.D. (1)
PMID 15692967, PMID 16790698, PMID 17469162, PMID 17485423, PMID 17717203, PMID 17901414, PMID 18245142, PMID 18641099, PMID 19017883, PMID 19436683, PMID 19583857, PMID 19776222, PMID 19892673, PMID 20740615, PMID 20958972, PMID 21791539, PMID 23723457, PMID 23739633, PMID 23830530, PMID 24958605, PMID 25176015, PMID 25336939, PMID 25452309, PMID 27012405, PMID 27330023, PMID 27401508, PMID 27469583, PMID 28012804, PMID 28038680, PMID 28390780, PMID 28544580, PMID 28606907, PMID 29099620, PMID 29866165, PMID 29898843, PMID 30049223, PMID 30651141, PMID 30741494, PMID 30850876, PMID 31424503, PMID 31430058, PMID 32150492, PMID 32171764, PMID 32423275, PMID 32671084, PMID 32673497, PMID 32967685, PMID 33289276, PMID 33289280, PMID 33350170
2018 (2), R01NR012009 (2), 2016 (1), 2017 (1), 2019 (1), I01CX002543 (1), P30CA015083 (1), R01HL089758 (1), R01HL089901 (1), U10CA037420 (1)